Key facts
- Cellevate’s last known valuation is $7.2M (Jun 2023).
- It has raised $10.5M; the latest was Later Stage VC ($2.3M) in Mar 2026.
- Notable investors include European Innovation Council, Almi Invest, Industrifonden, Nordic Mentor Network For Entrepreneurship, Mats Leifland — 7 tracked in total.
- Cellevate has filed 1 Form D with the SEC, most recently Jun 2025 ($25K sold to 1 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Cellevate
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellevate are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellevate
Developer of cell culture technology intended to create nanofiber-based systems for biomanufacturing processes. The company offers nanofiber microcarriers, cell culture systems, 3D cell culture platforms, and bioprocessing materials, enabling biopharmaceutical companies and researchers access to tools for cell and gene therapy production and vaccine manufacturing.
- Sector
- Healthcare
- HQ
- Lund, Sweden
- Founded
- 2014
- Employees
- 23
- Website
- cellevate.com/
- Ownership
- Privately Held (backing)
Cellevate doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellevate shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellevate in its N-PORT filings yet. We sweep new filings monthly.